Dr. Albert Bourla became Pfizer’s CEO months before the COVID-19 pandemic took hold of the US. Under his leadership, Pfizer manufactured 3 billion doses of the first FDA-approved vaccine in the first year, which led to record-breaking earnings. Yet over the past few years, post-pandemic sales slumps, patent cliffs and vaccine skepticism have driven down Pfizer’s earnings. In this episode of Fortune 500: Titans and Disruptors of Industry, Fortune’s Editor-in-Chief Alyson Shontell sits down with Bourla to talk about how he is answering this new set of challenges with science, innovation and optimistic leadership.
Learn more about your ad choices. Visit megaphone.fm/adchoices
